Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US90184D1000
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG006KDCHJ4
TWST
Twist Bioscience Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Twist Bioscience Corp
ISIN
US90184D1000
TICKER
TWST
MIC
XNAS
REUTERS
TWST.OQ
BLOOMBERG
TWST US
Tue, 25.02.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will particip...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.02.2025       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 123,024 equity awards, consisting of 72,394 restricted stock units (“RSUs”...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.02.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under th...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.01.2025       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, before the opening of the market on February 3, 2025. The company plans to hold a con...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.12.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.11.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.11.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the 7th Annual E...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.11.2024       Twist Bioscience
US90184D1000

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 147,800 equity awards, consisting of 110,300 restricted st...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.10.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with a proprietary Twist-developed enzyme to enable throughput at a low cost, and acc...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.10.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the market on November 18, 2024...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 22.10.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Ro...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 15.10.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, res...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.09.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the U.S. Green Building Council (USGBC) awarded the company’s Wilsonville, OR facility LEED certification, meeting sustainability standards for its building, operat...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.09.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its 2024 corporate responsibility report detailing Twist’s approach to sustainability, social responsibility and ethics. The report highlights Twist’s ongoing commitment...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.08.2024       Twist Bioscience
US90184D1000

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird Global Healthcare Conference 2024 in New York City on Tuesday, September 10...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.02.2023       Twist Bioscience
US90184D1000

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 10, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.02.2023       Twist Bioscience
US90184D1000

Los Angeles, California--(Newsfile Corp. - February 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 9, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of Califor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.02.2023       Twist Bioscience
US90184D1000

Los Angeles, California--(Newsfile Corp. - February 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.02.2023       Twist Bioscience
US90184D1000

Did you lose money on investments in Twist Bioscience Corporation? If so, please visit Twist Bioscience Corporation Shareholder Class Action Lawsuit or contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com to discuss your rights. New York,...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 09.02.2023       Twist Bioscience
US90184D1000

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 8, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 8, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of Califor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.02.2023       Twist Bioscience
US90184D1000

San Francisco, California--(Newsfile Corp. - February 8, 2023) - Hagens Berman urges Twist Bioscience Corporation (NASDAQ: TWST) investors who suffered significant losses to submit your losses now.Class Period: Dec. 13, 2019 - Nov. 14, 2022Lead Plaintiff Deadline: Feb. 10, 2023Visit: www.hbsslaw.com/investor-fraud/TWSTContact An Attorney Now: TWST@...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.02.2023       Twist Bioscience
US90184D1000

Los Angeles, California--(Newsfile Corp. - February 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.02.2023       Twist Bioscience
US90184D1000

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 7, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 7, 2023) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Twist Bioscience Corporation (NASDAQ: TWST).Shareholders who purchased shares of TWST during the class period listed are encouraged to contact the firm regarding possible Lead Pl...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 7, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Twist Bioscience Corporation (NASDAQ: TWST) between December 13, 2019 and November 14, 2022, both dates inclusive (the "Class Period"), of the important February 10, 2023 lead plaintiff deadline.S...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.02.2023       Twist Bioscience
US90184D1000

Los Angeles, California--(Newsfile Corp. - February 7, 2023) - Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST).Class Period: December 13, 2019 - November 14, 2022L...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 7, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of Califor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.02.2023       Twist Bioscience
US90184D1000

Los Angeles, California--(Newsfile Corp. - February 7, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.02.2023       Twist Bioscience
US90184D1000

San Francisco, California--(Newsfile Corp. - February 6, 2023) - Hagens Berman urges Twist Bioscience Corporation (NASDAQ: TWST) investors who suffered significant losses to submit your losses now.Class Period: Dec. 13, 2019 - Nov. 14, 2022Lead Plaintiff Deadline: Feb. 10, 2023Visit: www.hbsslaw.com/investor-fraud/TWSTContact An Attorney Now: TWST@...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.02.2023       Twist Bioscience
US90184D1000

Radnor, Pennsylvania--(Newsfile Corp. - February 6, 2023) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against Twist Bioscience Corporation ("Twist") (NASDAQ: TWST) on behalf of investors who purchased or acquired Twist common stock between December 13, 2019, an...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.02.2023       Twist Bioscience
US90184D1000

Los Angeles, California--(Newsfile Corp. - February 6, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 6, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of Califor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.02.2023       Twist Bioscience
US90184D1000

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 5, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 3, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Twist Bioscience Corporation (NASDAQ: TWST) between December 13, 2019 and November 14, 2022, both dates inclusive (the "Class Period"), of the important February 10, 2023 lead plaintiff deadline.S...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.02.2023       Twist Bioscience
US90184D1000

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 3, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.02.2023       Twist Bioscience
US90184D1000

Los Angeles, California--(Newsfile Corp. - February 3, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Twist Bioscience Corporation ("Twist" or "the Company") (NASDAQ: TWST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 2, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Twist an...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 2, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Twist Bioscience Corporation (NASDAQ: TWST) between December 13, 2019 and November 14, 2022, both dates inclusive (the "Class Period"), of the important February 10, 2023 lead plaintiff deadline.S...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.02.2023       Twist Bioscience
US90184D1000

Radnor, Pennsylvania--(Newsfile Corp. - February 2, 2023) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against Twist Bioscience Corporation ("Twist") (NASDAQ: TWST) on behalf of investors who purchased or acquired Twist common stock between December 13, 2019, an...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 2, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of Califor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.02.2023       Twist Bioscience
US90184D1000

San Francisco, California--(Newsfile Corp. - February 2, 2023) - Hagens Berman urges Twist Bioscience Corporation (NASDAQ: TWST) investors who suffered significant losses to submit your losses now. Class Period: Dec. 13, 2019 - Nov. 14, 2022Lead Plaintiff Deadline: Feb. 10, 2023Visit: www.hbsslaw.com/investor-fraud/TWST Contact An Attorney Now: TWS...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.02.2023       Twist Bioscience
US90184D1000

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - February 1, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.02.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - February 1, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of Califor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.02.2023       Twist Bioscience
US90184D1000

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Twist To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - January 31, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Twist Bioscience...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.02.2023       Twist Bioscience
US90184D1000

San Francisco, California--(Newsfile Corp. - January 31, 2023) - Hagens Berman urges Twist Bioscience Corporation (NASDAQ: TWST) investors who suffered significant losses to submit your losses now.Class Period: Dec. 13, 2019 - Nov. 14, 2022Lead Plaintiff Deadline: Feb. 10, 2023Visit: www.hbsslaw.com/investor-fraud/TWST Contact An Attorney Now: TWST...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.01.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - January 31, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Twist Bioscience Corporation (NASDAQ: TWST) between December 13, 2019 and November 14, 2022, both dates inclusive (the "Class Period"), of the important February 10, 2023 lead plaintiff deadline.S...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.01.2023       Twist Bioscience
US90184D1000

New York, New York--(Newsfile Corp. - January 31, 2023) - Levi & Korsinsky, LLP notifies investors in Twist Bioscience Corporation ("Twist" or the "Company") (NASDAQ: TWST) of a class action securities lawsuit.The lawsuit on behalf of Twist investors has been commenced in the the United States District Court for the Northern District of Califor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.01.2023       Twist Bioscience
US90184D1000

Did you lose money on investments in Twist Bioscience Corporation? If so, please visit Twist Bioscience Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. New York, New Yor...
Read more
Twist Bioscience
Technical Analysis Termsheets Terminal
Permalink